tbuckley/cabot-search huggingface dataset:
Assessing the Gold Standard — Lessons from the History of RCTs
Authors: Laura E. Bothwell, Jeremy A. Greene, Scott H. Podolsky, David S. Jones
Journal: New England Journal of Medicine (2016)

Randomized, controlled trials have become the gold standard of medical knowledge. Yet their scientific and political history offers lessons about the complexity of medicine and disease and the economic and political forces shaping the production and circulation of knowledge.
AB0361 Rheumatoid Cachexia: Prevalence and Associated Factors
Authors: L. Medrare, A. Ngeuleu, A. Mahdi, I. Benslama, T. Lakhdar, H. Rkain, F. Allali, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> The purpose of this study was to determine the prevalence of rheumatoid cachexia and analyze factors that might be associated with it. <h3>Methods</h3> This was a cross-sectional study using the data from 83 patients with rheumatoid arthritis (RA). Demographic and socio-economic parameters were collected. The disease activity was assessed by the tender joint count (TJC), swollen joint count (SJC), pain assessed by a visual analogue scale (pVAS), global activity disease evaluated by the physician and the patient using a visual analogue scale (gVAS) and blood markers of inflammation (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)). Anthropometric measurements (weight, height, waist circumference (WC), body mass index (BMI)) were recorded for each patient. WC was interpreted and classified according to recommendations of WHO in 2 categories of risk of metabolic complications: low risk (WC≤93.9 cm in men and WC ≤79.9 cm in women) and high risk (WC≥102.0 cm in men and 88.0 cm for WC≥ woman). The skinfold thickness was measured using the clamp Harpenden in 4 sites: triceps, biceps, subscapular and suprailiac regions. Fat-free mass index (FFMI) and fat mass index (FMI) were calculated using the equation of Durnin and Wormersley and the equation of Siri. Rheumatoid cachexia has been defined by an FFMI &lt;10th percentile and a FMI&gt;90th percentile. <h3>Results</h3> 83 patients were included with a mean age of 51.7±13.3 years and a female predominance (87%). The median of RA duration was 7 years [4 to 14]. 9 patients (15.5%) have a rheumatoid cachexia, 8 of them (88.9%) are women with a normal BMI. The rheumatoid cachexia was associated with advanced age and a high metabolic risk (p&lt;0.001). There was no association between rheumatoid cachexia and parameters of disease activity: TJC (p=0.9); SJC (p=0.2); pVAS pain (p=0.5); gVAS (p=0.6); ESR (p=0.5); CRP (p=0.3). <h3>Conclusions</h3> This study suggests that rheumatoid cachexia is frequent in patients suffering from RA, which may be associated with advanced age, a normal BMI and the risk of metabolic complications. These results should be verified by studies on a larger scale. <h3>Disclosure of Interest</h3> None declared
Borderline Resectable Pancreatic Cancer
Authors: John A. Windsor
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Clinical implications of adult developmental theory
Authors: C A Colarusso, R A Nemiroff
Journal: American Journal of Psychiatry (1987)

Multidisciplinary studies of adulthood have revolutionized thinking about developmental processes during the second half of life. These ideas are just beginning to be integrated with clinical theory and practice. The elaboration of the interface between the rapidly expanding developmental theory of normal adulthood and clinical intervention with older patients is a psychiatric frontier. Illustrating with clinical examples, the authors offer a rationale for using new diagnostic tools, suggest a revision of the theory of transference to include sources beyond childhood, and describe unique transference paradigms in older patients as well as equally phase-specific countertransference responses in their therapists.
PTH-110 Long term survival following treatment for hepatocellular carcinoma in patients with hereditary haemochromatosis
Authors: M Mcphail, L Abbott, G Al-Kadhimi, P Kane, J Karani, N Heaton, J O’Grady, A Bomford, A Suddle
Journal: Gut (2015)

<h3>Introduction</h3> Hepatocellular carcinoma (HCC) rates are higher in patients with hereditary haemochromatosis (HH) compared to other aetiologies. Survival with or without liver transplantation (LT) is often deemed less favourable. Modern mortality rates post LT or following loco-regional therapy (LRT) are not well reported therefore prognostic pessimism may be misplaced. <h3>Method</h3> Consecutive patients with HH and HCC diagnosed between 2000 and 2013 at our institution were studied. Patients were offered curative liver transplantation (LT), radiofrequency ablation (RFA) or surgical resection; or, non-curative treatment with trans-arterial chemo-embolization (TACE), sorafenib or symptom control according to performance status and Barcelona Clinic Liver Cancer (BCLC) stage. Patient characteristics recorded at time of first HCC diagnosis included demographics, tumour size and multiplicity, severity of liver disease, serum ferritin (SF, as a proxy for HH treatment) and alphafetoprotein (AFP). The primary end-point was all-cause mortality. <h3>Results</h3> Forty-one patients (median (range) age 67(44–78) years, 97% male, MELD 8(5–31)) made up the study cohort with a median follow up of 22(3–126) months. Thirty-six patients had cirrhosis and median SF was 256(27–5718) mg/L and median AFP 29(2–197926) kIU/L. Twenty-seven (66%) patients had solitary tumours, 44% were BCLC stage A, 27% BCLC-B, 10% BCLC-C and 5% BCLC-D. TACE was the commonest LRT choice in 21 (49%) patients. Four patients (9%) underwent surgical resection and RFA was performed in 5 (12%) patients. Fourteen patients (32%) underwent LT. Median survival was 27 (95% CI 17–41) months. Patients with &gt;1 HCC did not have decreased survival compared to those with a single tumour (p = 0.386). Five-year survival for patients receiving curative therapy was 77% (80% for LT, 67% for surgery/RFA), and for those undergoing non-curative therapy 5-year survival was 15% (23% for patients receiving TACE). For BCLC-A patients 5-year survival was 64%, 50% for BCLC-B patients and 9% for BCLC-C/D patients (p = 0.002). On age-adjusted Cox regression survival analysis BCLC-C/D stage was independently associated with poor survival (Hazard Ratio 4.05 (1.29–12.63), p = 0.016) but not serum AFP, SF or the presence of cirrhosis. <h3>Conclusion</h3> Patients with HCC in the context of HH can achieve comparable survival rates following curative modalities to those with other aetiologies. The BCLC staging system accurately stratifies survival and excellent 5-year survival is possible following LT in selected patients. <h3>Disclosure of interest</h3> None Declared.
Early-Treatment Diabetic Retinopathy Study
Authors: T A Rice
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SP0187 Does the Diagnosis Matter for Exercise Dosage?
Authors: H. Alexanderson
Journal: Annals of the Rheumatic Diseases (2015)

Exercise has become an important part of the treatment for patients with rheumatic diseases. For many patients, guidelines for exercise and physical activity are similar to those for healthy. Are these guidelines applicable to all diagnosis? During this session, current evidence on recommended levels of exercise in patients with fibromyalgia and systemic inflammatory diseases with internal organ involvement will be discussed. Take home messages: –Given the heterogeneous nature of the rheumatic diseases, exercise dosage is probably more dependent on individual disease activity, impairments, activity limitations and aspects of quality of life, than the actual diagnosis. –Patients with severe fibromyalgia symptoms should be exercising with lower duration, frequency and intensity. –The scientific evidence on safety and effects of moderate-to-intensive exercise is very limited for patients with moderate-to-severe vital-organ involvement. For safety, these patients are recommended supervised exercise on lower intensity with close follow-up. <h3>Disclosure of Interest</h3> None declared
Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis
Authors: C Sirard, T Lapidot, J Vormoor, JD Cashman, M Doedens, B Murdoch, N Jamal, H Messner, L Addey, M Minden, P Laraya, A Keating, A Eaves, PM Lansdorp, CJ Eaves, JE Dick
Journal: Blood (1996)
Ongoing outbreak of measles in Oslo, Norway, January–February 2011
Authors: K Vainio, K Rønning, T W Steen, T M Arnesen, G Ånestad, S Dudman
Journal: Eurosurveillance (2011)

Between 19 January and 17 February 2011, 10 cases of measles (eight laboratory-confirmed and two probable) were reported in Oslo with the majority of cases in a mainly unvaccinated immigrant community. Of these, two cases were identified outside the immigrant community, in Norwegian children.
Initial epidemiological findings in the European Union following the declaration of pandemic alert level 5 due to influenza A (H1N1)
Authors: None ECDC Technical Emergency Team
Journal: Eurosurveillance (2009)

The recent detection of a novel influenza A(H1N1) virus has led to the first WHO declaration of a Public Health Event of International Concern under the International Health Regulations (IHR 2005). Here we review the early epidemiological findings of confirmed cases in Mexico, the United States, Canada and EU/EFTA countries. Strengthened surveillance and continued, transparent communication across public health agencies globally will be necessary in coming months.
Postmastectomy radiotherapy: questions for the twenty-first century.
Authors: A Recht, H Bartelink, A Fourquet, B Fowble, B G Haffty, J R Harris, J Kurtz, B McCormick, I A Olivotto, L Rutqvist, L J Solin, J Yarnold
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.8.2886 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9704743 Postmastectomy radiotherapy: questions for the twenty-first century. A RechtxA RechtSearch for articles by this author , H BartelinkxH BartelinkSearch for articles by this author , A FourquetxA FourquetSearch for articles by this author , B FowblexB FowbleSearch for articles by this author , B G HafftyxB G HafftySearch for articles by this author , J R HarrisxJ R HarrisSearch for articles by this author , J KurtzxJ KurtzSearch for articles by this author , B McCormickxB McCormickSearch for articles by this author , I A OlivottoxI A OlivottoSearch for articles by this author , L RutqvistxL RutqvistSearch for articles by this author , L J SolinxL J SolinSearch for articles by this author , J YarnoldxJ YarnoldSearch for articles by this author Show More Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA. [email protected] https://doi.org/10.1200/JCO.1998.16.8.2886 First Page PDF © 1998 by American Society of Clinical Oncology
Fatal Reactions to Penicillin
Authors: Vernon M. Smith
Journal: New England Journal of Medicine (1957)

SERIOUS anaphylactic reactions to penicillin are an increasing clinical problem. It has been estimated that more than 1000 deaths from such reactions have occurred in the United States alone.1 Practically all these deaths resulted from immediate anaphylactic shock reactions to penicillin rather than from a delayed urticarial or serum-sickness type of reaction. Most of them occurred in physicians' offices after penicillin injections administered for other than life-saving purposes.A more restrictive evaluation of the indications for penicillin therapy might be expected to decrease the number of serious reactions by reducing the number of persons who are exposed to the drug. . . .
Trichinellosis: still a concern for Europe
Authors: J Dupouy-Camet
Journal: Eurosurveillance (2006)

Trichinellosis is a zoonotic disease caused by the ingestion of raw meat containing larvae of the nematode Trichinella. Four species of Trichinella are found in Europe : Trichinella spiralis (cosmopolitan), T. britovi (in wildlife from mountainous areas), T. nativa (in wildlife from colder and northern regions) and T. pseudospiralis (a cosmopolitan nonencapsulating species). Human trichinellosis causes high fever, facial oedema, myositis and eosinophilia. It can be a serious disease, particularly in elderly patients in whom neurological or cardiovascular complications can lead to death.
Respiratory Function in Pulmonary Tuberculosis
Authors: J Nagano
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Presence of mcr-1-positive Enterobacteriaceae in retail chicken meat but not in humans in the Netherlands since 2009
Authors: Marjolein F Kluytmans–van den Bergh, Pepijn Huizinga, Marc J Bonten, Martine Bos, Katrien De Bruyne, Alexander W Friedrich, John W Rossen, Paul H Savelkoul, Jan A Kluytmans
Journal: Eurosurveillance (2016)

Recently, the plasmid-mediated colistin resistance gene mcr-1 was found in Enterobacteriaceae from humans, pigs and retail meat in China. Several reports have documented global presence of the gene in Enterobacteriaceae from humans, food animals and food since. We screened several well-characterised strain collections of Enterobacteriaceae , obtained from retail chicken meat and hospitalised patients in the Netherlands between 2009 and 2015, for presence of colistin resistance and the mcr-1 gene. A total of 2,471 Enterobacteriaceae isolates, from surveys in retail chicken meat (196 isolates), prevalence surveys in hospitalised patients (1,247 isolates), clinical cultures (813 isolates) and outbreaks in healthcare settings (215 isolates), were analysed. The mcr-1 gene was identified in three (1.5%) of 196 extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates from retail chicken meat samples in 2009 and 2014. Two isolates were obtained from the same batch of meat samples, most likely representing contamination from a common source. No mcr-1 -positive isolates were identified among 2,275 human isolates tested. All mcr -1-positive isolates were colistin-resistant (minimum inhibitory concentration (MIC) &gt; 2 mg/L). Our findings indicate that mcr -1-based colistin-resistance currently poses no threat to healthcare in the Netherlands. They indicate however that continued monitoring of colistin resistance and its underlying mechanisms in humans, livestock and food is needed.
A New Label for Mifepristone
Authors: Michael F. Greene, Jeffrey M. Drazen
Journal: New England Journal of Medicine (2016)

The vicissitudes of life produce pregnancies which may be unwanted, or which may impair “health” … which, in the full setting of the case, may create such suffering, dislocations, misery, or tragedy as to make an early abortion the only civilized step to take. — Justice William O. Douglas, January 22, 1973, writing a concurring opinion in Roe v. Wade Whenever a sponsor conducts phase 3 trials of a new molecular entity to support Food and Drug Administration (FDA) approval for marketing, there are strong incentives to conduct the trials under conditions that will maximize efficacy and minimize the number . . .
In the Air, Flight Nurses Take Charge of Patients
Authors: H KLEINMAN, M K COONEY, C B NELSON, R R OWEN, L BOYD, G SWANDA
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Walk
Authors: Laura Bonner
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Butorphanol
Authors: Jan Koch-Weser, Leroy D. Vandam
Journal: New England Journal of Medicine (1980)

BUTORPHANOL tartrate (Stadol, Dorphanol) is one of a species of narcotic analgesics or opioids that combine the properties of the common opioids and the actions of an opioid antagonist such as the widely used naloxone (Narcan).1 The introduction of this completely synthetic morphinan derivative (Fig. 1) coincided with the advent of another agonist-antagonist, nalbuphine hydrochloride,2 3 4 and with interest in a third, similar compound, buprenorphine.HistoryThe addition of an n-allyl radical to codeine, in 1915, gave rise to n-allyl norcodeine that could abolish the respiratory depressant action of morphine. Over 25 years later, n-allyl normorphine or nalorphine was synthesized; it . . .
Chronic Atrophic Gastritis: Identification of Different Varieties&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: Alvin J. Cox, M. D.
Journal: JNCI Journal of the National Cancer Institute (1949)

Chronic Atrophic Gastritis: Identification of Different Varieties Get access Alvin J. Cox, M. D. Alvin J. Cox, M. D. Department of Pathology, Stanford University School of Medicine, San Francisco Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 2, October 1949, Pages 523–532, https://doi.org/10.1093/jnci/10.2.523 Published: 01 October 1949